20.500.12556/DiRROS-30312 Early unfractionated heparin treatment in patients with STEMI - trial design and rationale The early unfractionated heparin (UFH) treatment in patients with ST-elevation myocardial infarction (STEMI) is a single-center, open-label, randomized controlled trial. The study population are patients with STEMI that undergo primary percutaneous coronary intervention (PPCI). The trial was designed to investigate whether early administration of unfractionated heparin immediately after diagnosis of STEMI is beneficial in terms of patency of infarctrelated coronary artery (IRA) when compared to established UFH administration at the time of coronary intervention. The patients will be randomized in 1:1 fashion in one of the two groups. The primary efficacy endpoint of the study is Thrombolysis in myocardial infarction (TIMI) flow grades 2 and 3 on diagnostic coronary angiography. Secondary outcome measures are: TIMI flow after PPCI, progression to cardiogenic shock, 30-day mortality, ST-segment resolution, highest Troponin I and Troponin I values at 24 hours. The safety outcome is bleeding complications. The study of early heparin administration in patients with STEMI will address whether pretreatment with UFH can increase the rate of spontaneous reperfusion of infarct-related coronary artery unfractionated heparin (UFH) treatment true false true Angleški jezik Ni določen Neznano 2026-06-19 11:40:02 2026-06-19 11:40:03 2026-06-20 03:49:02 0000-00-00 00:00:00 2024 0 0 Nasl. z nasl. zaslona; Opis vira z dne 12. 8. 2024; str. 1-7 No. 5 Vol. 19 2024 0000-00-00 Zaloznikova Objavljeno NiDoloceno 0000-00-00 0000-00-00 0000-00-00 61 Y506-0087 10.1371/journal.pone.0303376 204202243 https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0303376 1 15edf5f7-6bb2-11f1-be3d-001a4af901a5 https://dirros.openscience.si/Dokument.php?lang=slv&id=45969 Univerzitetni klinični center Ljubljana 0 0 0